Want to see SRXH full AI Analyst Report?
SRx Health Solutions (SRXH) AI Stock Analysis
SRx Health Solutions
(NYSE MKT:SRXH)
The score is held down primarily by weak and volatile financial performance (losses and deep negative free cash flow) and bearish technicals (price below key moving averages with negative MACD). Valuation is only modestly supportive due to a dividend despite unprofitable earnings, while corporate events are a relative positive (compliance restored, buyback/dividend, strategic initiatives) but do not offset the core earnings-and-cash risks.
SRx Health Solutions (SRXH) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $9.94M
- Dividend Yield
- 4.95%
- Average Volume (3M)
- 734.36K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- -0.06
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 7
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Software - Application
SRx Health Solutions Business Overview & Revenue Model
Company Description
SRX Global Inc. develops artificial intelligence (AI)-powered solutions designed to improve decision-making, streamline operations, and strengthen risk management. The company is headquartered in Tampa, Florida.
SRx Health Solutions Earnings Call Summary
The earnings call highlighted significant improvements in profitability measures, including gross profit margins, net loss, and EBITDA. Revenue growth, particularly in the fourth quarter and international markets, was strong. However, there were challenges such as a decline in annual net revenues and ongoing EBITDA losses. Overall, the company's strategic pivots and financial health improvements contributed to a positive outlook.
Q4-2024 Updates
Positive Updates
Negative Updates
Company Guidance
In the fourth quarter of 2024, Better Choice Company reported notable financial achievements and strategic advancements. The company delivered a gross profit margin of 37%, improving by over 600 basis points year-over-year, and adjusted EBITDA loss was reduced by 78% to approximately $1.9 million on annual net revenues of $35 million. The company experienced a 26% increase in fourth-quarter revenue, driven by 32% growth on platforms like Amazon and Chewy, and 18% international growth. Key operational improvements included a 22% reduction in SG&A expenses and a more than 40% reduction in inventory, leading to a working capital position of $7.9 million. Additionally, Better Choice successfully negotiated a $6.2 million gain from extinguishing debt and accounts payable. The company's focus on e-commerce channels is expected to continue propelling growth into 2025, as evidenced by the profitability improvements and strategic exits from non-core sales channels. Looking forward, Better Choice is poised for expanded growth through its acquisition of SRx Health Solutions, which is anticipated to close in April, further solidifying its position as a leader in the pet health and wellness sector.
SRx Health Solutions Financial Statement Overview
Summary
Overall fundamentals are weak: income statement results are inconsistent and largely loss-making, and cash flow quality is a major concern with deeply negative free cash flow and unreliable operating cash flow. The TTM balance sheet looks improved with zero reported debt, but prior leverage volatility and weak returns on equity reduce confidence in financial stability.
Income Statement
28NegativeBalance Sheet
50NeutralCash Flow
18Very Negative| Breakdown | TTM | Sep 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -37.41M | 6.53M | 50.30M | 161.55M | 92.63M | 58.63M |
| Gross Profit | -12.16M | 1.53M | 18.49M | 32.07M | 13.31M | 17.47M |
| EBITDA | -7.05M | -7.98M | 6.40M | -9.67M | 1.01M | 10.58M |
| Net Income | -40.42M | -45.01M | -241.60K | -15.13M | -2.45M | 3.80M |
Balance Sheet | ||||||
| Total Assets | 145.36M | 8.40M | 22.72M | 42.05M | 34.79M | 98.67M |
| Cash, Cash Equivalents and Short-Term Investments | 49.69M | 1.31M | 6.41M | 2.07M | 1.66M | 36.89M |
| Total Debt | 0 | 4.47M | 2.02M | 39.38M | 17.85M | 13.16M |
| Total Liabilities | 2.37M | 8.00M | 120.62M | 70.80M | 33.86M | 24.91M |
| Stockholders Equity | 142.99M | 407.00K | 13.91M | 15.08M | 62.20M | 73.76M |
Cash Flow | ||||||
| Free Cash Flow | -8.36M | -8.14M | -5.97M | 79.00K | -20.75M | -15.56M |
| Operating Cash Flow | 101.00K | -8.14M | -5.91M | 97.00K | -20.55M | -15.11M |
| Investing Cash Flow | -34.47M | 5.91M | -3.06M | -18.00K | -198.00K | -449.89K |
| Financing Cash Flow | 79.09M | 12.17M | 7.08M | -5.10M | 1.28M | 47.36M |
SRx Health Solutions Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRXH, the sentiment is Negative. The current price of 1.01 is below the 20-day moving average (MA) of 1.23, below the 50-day MA of 1.49, and below the 200-day MA of 5.06, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 24.73 is Positive, neither overbought nor oversold. The STOCH value of 23.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRXH.
SRx Health Solutions Risk Analysis
SRx Health Solutions disclosed 96 risk factors in its most recent earnings report. SRx Health Solutions reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksSRx Health Solutions Peers Comparison
Overall Rating
GRFS71Outperform
OGN53Neutral
SRXH44Neutral
CTOR41.55Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | $7.31B | 16.38 | 8.43% | 3.48% | 6.84% | 61.67% | |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| 53Neutral | $3.63B | 17.52 | 22.11% | 0.58% | -3.21% | -58.19% | |
| 44Neutral | $20.39M | -0.01 | -97.77% | 4.95% | ― | ― | |
| 42Neutral | $51.51M | -1.16 | -102.97% | ― | ― | ― |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SRXH | Srx Health Solutions Inc. | 1.01 | -16.89 | -94.36% | |
| GRFS | Grifols SA | 8.10 | -1.23 | -13.16% | |
| SCLX | Scilex Holding Company | 1.85 | -9.27 | -83.36% | |
| OGN | Organon & Co. | 13.84 | 7.18 | 107.96% | |
| CTOR | Citius Oncology, Inc. | 0.55 | -1.12 | -66.83% | |
| MIRA | MIRA Pharmaceuticals, Inc. | 0.55 | -1.15 | -67.76% |
SRx Health Solutions Corporate Events
SRx Health Solutions to Acquire CERo Therapeutics Subsidiary
PositiveOn October 6, 2026, SRX Global Inc. entered into a Stock Purchase Agreement to acquire all outstanding shares of CERo Therapeutics, Inc. from CERo Therapeutics Holdings, Inc., with CERo becoming a wholly owned subsidiary at closing. The consideration...
SRx Launches AI-Powered Actively Managed ETF Platform
PositiveOn October 6, 2026, SRX Global Inc. announced it is committing $1.5 million to launch a family of actively managed, AI-powered exchange traded funds through its EMJX platform, in partnership with Kupa AI and its co-founder Andy Kim. The ETF family wi...
SRx Health Solutions Announces Stock Repurchase Plan Amendment
PositiveOn August 27, 2026, SRX Global Inc. entered into a Securities Purchase Agreement with accredited investors, under which the buyers acquired 3,579 shares of Series C convertible preferred stock for an aggregate $2.825 million, with the securities conv...
SRx Health Solutions Secures Major CERo Financing Deal
PositiveOn August 31, 2026, SRX Global Inc. announced it had acquired senior secured debt in CERo Therapeutics Holdings, consolidating prior convertible notes and providing up to $11.67 million in financing, backed by first-priority liens on CERo’s equ...
SRx Health Solutions Completes Series C Preferred Financing
PositiveOn August 27, 2026, SRX Global Inc. entered into a private placement Securities Purchase Agreement with accredited investors, issuing 3,579 shares of Series C convertible preferred stock for $2.86 million, paid via assignment of CERO Therapeutics Hol...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 08, 2026